Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

The scope, funding and publication of musculoskeletal clinical trials performed in Australia

- Featured Image

According to the recently published 2010 Global Burden of Disease study, musculoskeletal (MSK) conditions have the fourth greatest impact on the health of the world’s population, accounting for 6.8% of the total disease burden.1 In considering disability alone, low back pain has the greatest impact on health, outranking ischaemic heart disease, chronic obstructive pulmonary disease and major depressive illness, with other MSK conditions ranked sixth and osteoarthritis ranked 11th.1

In Australia, MSK conditions are the leading contributor to total disability burden (27.4%), and are second only to cancer (15.3% versus 16.2%) when death is also considered.2 They are the most common reason for accessing health care services,3 and in financial terms, contribute to 7.5% of total health expenditure (costing around $4 billion).4 Given their large burden on the Australian population, osteoarthritis, rheumatoid arthritis and osteoporosis were designated National Health Priority Areas (NHPAs) in 2002.5 Importantly, the burden from MSK conditions is increasing as the…